<DOC>
	<DOC>NCT03070782</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).</brief_summary>
	<brief_title>Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<criteria>Key Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or peripheral artery disease Lp(a) plasma level â‰¥ 60 mg/dL Must be on standardofcare preventative therapy for other than elevated Lp(a) CVD risk factors Key Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/TIA Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major noncardiac surgery, or lipoprotein apheresis Heart failure New York Heart Association (NYHA) class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IONIS-APO(a)-LRx</keyword>
	<keyword>AKCEA-APO(a)-LRx</keyword>
</DOC>